Cantor Fitzgerald Maintains Overweight on Lucid Diagnostics, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has maintained an Overweight rating on Lucid Diagnostics (LUCD) but lowered the price target from $3.8 to $3.
March 27, 2024 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating on Lucid Diagnostics but reduces the price target from $3.8 to $3.
The reduction in price target by Cantor Fitzgerald, despite maintaining an Overweight rating, could lead to short-term negative sentiment among investors, potentially impacting LUCD's stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100